Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: rhCG Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

NCT02069808
View directory record Official record
Conditions
Egg Donation
Interventions
Follistim, Ganirelix, Menotropins, Leuprolide, Transvaginal ultrasound guided needle aspiration of oocytes
Drug · Procedure
Lead sponsor
Michigan Reproductive Medicine
Other
Eligibility
18 Years to 28 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bloomfield Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 21, 2026, 1:28 PM EDT
Withdrawn Early Phase 1 Interventional

Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction

NCT01422733
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone, dexamethasone, Cosyntropin, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 16 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 21, 2026, 1:28 PM EDT
Recruiting Phase 1 Interventional

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

NCT04886726
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
uhCG/EGF
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 1:28 PM EDT
Not listed Not applicable Interventional

Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422759
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Spironolactone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

NCT00989781
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
3-D Ultrasound, recombinant human chorionic gonadotropin, Recombinant human follicle stimulating hormone, Adrenocorticotropin, Dexamethasone, Glucose
Radiation · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 21, 2026, 1:28 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709
View directory record Official record
Conditions
Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions
GnRH agonist, hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
21 Years to 33 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 21, 2026, 1:28 PM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 21, 2026, 1:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion

NCT02179944
View directory record Official record
Conditions
Undesired Pregnancy
Interventions
Not listed
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 21, 2026, 1:28 PM EDT
Not listed Phase 1 Interventional

Assessing Ketorolac (Toradol) at Oocyte Retrieval

NCT06026553
View directory record Official record
Conditions
Infertility, Infertility, Female, Oocyte Retrieval, Postoperative Pain, Embryo Transfer
Interventions
Ketorolac (Toradol), Placebo (saline)
Drug · Other
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 21, 2026, 1:28 PM EDT
Not listed Not applicable Interventional

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

NCT04447872
View directory record Official record
Conditions
Infertility, Diminished Ovarian Reserve, IVF
Interventions
Timing of injectable gonadotropins
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 21, 2026, 1:28 PM EDT
Terminated Not applicable Interventional Results available

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

NCT00700778
View directory record Official record
Conditions
BRCA1 Mutation, Breast Cancer
Interventions
recombinant human chorionic gonadotropin, microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis, needle biopsy
Biological · Genetic · Other + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

NCT01154192
View directory record Official record
Conditions
PCOS
Interventions
Dexamethasone, recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 21, 2026, 1:28 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters

NCT00006445
View directory record Official record
Conditions
Down Syndrome, Chromosome Abnormalities
Interventions
Ultrasound, Serum screen
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
16 Years to 45 Years · Female only
Enrollment
38,000 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Denver, Colorado • Boston, Massachusetts • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2007 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

NCT00839319
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, placebo hCG (no active ingredient), hCG (human chorionic gonadotropin), Testosterone gel
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 21, 2026, 1:28 PM EDT
Enrolling by invitation Phase 2 Interventional

Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm

NCT07481370
View directory record Official record
Conditions
Oligospermia, Azoospermia, Nonobstructive, Infertility
Interventions
isotretinoin, Human chorionic gonadotrophin (hCG)
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 50 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 21, 2026, 1:28 PM EDT
Not listed No phase listed Observational

Proteomics & Glyco-Proteomic Analysis of Follicular Fluid

NCT01487486
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Normal Volunteers
Interventions
IVF Antagonist Protocol
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 2Phase 3 Interventional

Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

NCT03440359
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse
Drug · Diagnostic Test · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 21, 2026, 1:28 PM EDT
Terminated Phase 2 Interventional Results available

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00938314
View directory record Official record
Conditions
Stroke
Interventions
human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of hCG on Receptivity of the Human Endometrium

NCT01786252
View directory record Official record
Conditions
Infertility, Subfertility
Interventions
human chorionic gonadotropin (hCG), Placebo Comparator (for hCG)
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Not applicable Interventional

Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?

NCT00907725
View directory record Official record
Conditions
Medical Abortion
Interventions
serum BhCG follow-up, ultrasonographic follow-up
Other
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 21, 2026, 1:28 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ovarian Contribution to Androgen Production in Adolescent Girls

NCT01421810
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obesity, Hyperandrogenism
Interventions
Dexamethasone, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 2 Interventional Results available

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

NCT00505752
View directory record Official record
Conditions
Infertility
Interventions
AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 36 Years · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 21, 2026, 1:28 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

NCT05343572
View directory record Official record
Conditions
Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Interventions
Plerixafor
Drug
Lead sponsor
Hugh Taylor
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Orange, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 1:28 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF

NCT01687712
View directory record Official record
Conditions
Infertility
Interventions
AFOLIA, Gonal-f® RFF
Drug
Lead sponsor
Fertility Biotech AG
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Tempe, Arizona • Encino, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 21, 2026, 1:28 PM EDT